SFT2D2 Antibody
Description
Biological Context of SFT2D2
SFT2D2 (UniProt ID: O95562) is a membrane-associated protein involved in retrograde vesicle transport between endocytic compartments and the Golgi apparatus . It is expressed in brain regions (prefrontal cortex, hippocampus) and immune cells (microglia, plasmacytoid dendritic cells) . Genetic studies identified rare variants (e.g., rs532193193) in SFT2D2 strongly associated with schizophrenia (OR = 1.13–1.22) .
Key Research Findings:
-
Clinical Utility: Anti-SFT2D2 IgG levels distinguish schizophrenia patients from controls with 95% specificity .
-
Mechanistic Insights: In ApoE⁻/⁻ mice (compromised blood-brain barrier), anti-SFT2D2 IgG induces synaptic loss, microglial activation, and psychosis-like behaviors .
Available Reagents (2025):
-
Validation: Antibodies show reactivity in human and mouse samples, with protein G purification (>95% purity) .
Pathophysiological Mechanisms
Anti-SFT2D2 antibodies may contribute to schizophrenia via:
-
Blood-Brain Barrier Penetration: Enhanced permeability in SCZ allows IgG entry, targeting CNS SFT2D2 .
-
Synaptic Effects: Reduced dendritic spine density in hippocampal neurons .
-
Immune Activation:
Research Limitations
Product Specs
Target Background
- Observational study of gene-disease association (HuGE Navigator). PMID: 19536175
- Observational study of gene-disease association (HuGE Navigator). PMID: 19064610
Q&A
SFT2D2 Antibody: Frequently Asked Questions for Academic Researchers
What experimental models are suitable for studying SFT2D2’s role in neuropsychiatric disorders?
-
Animal models: ApoE-/- mice with compromised blood-brain barriers (BBB) mimic autoimmune aspects of schizophrenia. Immunization with SFT2D2 peptides induces behavioral deficits (e.g., impaired pre-pulse inhibition) and neuroinflammation .
-
Human postmortem studies: Analyze prefrontal cortex, hippocampus, and striatum tissues for SFT2D2 mRNA/protein levels, as these regions show dysregulation in schizophrenia .
-
In vitro systems: Use plasmacytoid dendritic cells (pDCs) or microglia, where SFT2D2 is highly expressed .
How do I reconcile contradictory data on SFT2D2 expression in schizophrenia?
Conflicting results may arise from:
-
Sample heterogeneity: Subtype-specific differences in schizophrenia cohorts (e.g., autoimmune vs. non-autoimmune subgroups).
-
Methodological variability:
-
Compensatory mechanisms: Upregulation in some brain regions (e.g., prefrontal cortex ) vs. downregulation in peripheral immune cells.
What are the functional implications of anti-SFT2D2 autoantibodies in schizophrenia pathophysiology?
-
Mechanism 1: Autoantibodies cross the BBB (enhanced in ApoE-/- mice ), bind neuronal SFT2D2, and alter dendritic spine density via microglial activation .
-
Mechanism 2: Overactive SFT2D2 in pDCs disrupts immune tolerance, triggering pro-inflammatory cytokine release (e.g., IL-6, TNF-α) .
-
Therapeutic insight: ROC analysis (28.57% sensitivity, 95% specificity ) suggests anti-SFT2D2 IgG as a biomarker for patient stratification.
How can I optimize SFT2D2 antibody-based assays for low-abundance targets?
-
Signal amplification: Use tyramide-based systems in ICC/IF.
-
Pre-absorption: Remove non-specific IgG using protein A/G beads.
-
Multiplexing: Pair with markers like GFAP (astrocytes) or Iba1 (microglia) to contextualize SFT2D2 expression .
-
Quantitative WB: Normalize to housekeeping proteins (e.g., β-actin) and validate linear detection range .
What are the pitfalls in interpreting SFT2D2 antibody reactivity in autoimmune assays?
-
False positives: Cross-reactivity with bacterial/viral antigens due to molecular mimicry.
-
Epitope masking: Post-translational modifications (e.g., phosphorylation) in patient-derived samples.
-
Batch variability: Antibody lot-to-lot differences in affinity (mitigate by validating each lot ).
